Zambia Greenlights Six-Month Injectable Antiretroviral to Combat HIV by 2030

Zambia has approved the six-month injectable antiretroviral lenacapavir (LEN) to combat HIV, aiming to eliminate it as a public health threat by 2030.

Zambias health minister announced the approval of lenacapavir (LEN), a six-month injectable antiretroviral for HIV prevention, on Friday, marking a significant public health initiative.
The introduction of LEN positions Zambia alongside South Africa in utilizing this innovative treatment, aiming to reduce new HIV infections and improve immune system health.
This initiative is part of Zambias broader strategy to eliminate HIV and AIDS as a public health threat by the year 2030, enhancing the nations healthcare response.

Why It Matters

This approval represents a critical step in the fight against HIV, potentially transforming prevention strategies across Africa. By targeting a significant reduction in HIV infections, Zambia aims to safeguard public health and improve the quality of life for countless individuals.